Officer Files Intent to Sell Over 100,000 Shares Following Option Exercise
CCCC has more than doubled off its 52-week low of $1.085 on elevated volume (3.3× avg).
Summary
An officer of C4 Therapeutics has filed a Form 144 to sell 101,175 shares, valued at approximately $378,849, following a stock option exercise.
Key Events · Ownership and Investor Activity · CCCC
-
Officer Files Intent to Sell Shares
Jolie M. Siegel, an Officer, filed a Form 144 indicating an intent to sell 101,175 shares of common stock.
-
Significant Value of Proposed Sale
The proposed sale has an approximate market value of $378,849.35.
-
Follows Stock Option Exercise
The shares to be sold were acquired through a stock option exercise on the same day as the proposed sale date.
-
Minor Dilution Relative to Outstanding Shares
The shares represent approximately 0.10% of the company's total outstanding shares.
Analysis · CCCC · Life Sciences
Jolie M. Siegel, an Officer of C4 Therapeutics, has filed a Form 144 indicating an intent to sell 101,175 shares of common stock, valued at approximately $378,849. This proposed sale follows the exercise of stock options. While common for liquidity or tax purposes, a reduction in direct insider ownership by an officer can be perceived as a slight negative signal, especially coming after the company recently announced strong financial results and a successful capital raise that extended its cash runway through 2028.
At the time of this filing, CCCC was trading at $3.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $350.3M. The 52-week trading range was $1.09 to $3.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.